RxDoctor Payments Data

Teri Lee

Family · Lenoir, NCNPI 1649810284

Payments from drug & device makers

What this record shows

This record is dominated by other: $32,500 of the $39,646 with a category attached, or 82.0%. Angiodynamics, Inc. accounts for 92.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $15,278 and has fallen 98.8% since, to $179 in 2025. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,646in general payments, 2019–2025

Across 118 payments — averaging $335.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$37K
  • Medtronic$1K
  • Johnson & Johnson$915
  • Pfizer$119
  • Smith+Nephew$91
  • Boston Scientific$66
  • plus $292 from 10 others

What the payments were for

  • Travel & lodging$8912%
  • Food & beverage$2,2766%
  • Education$3,97910%
  • Other$32,50082%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,646 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$44,205
Medicare patients
368
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban207$147,525
EliquisApixaban119$102,950
Pentoxifylline344$9,773
Nitroglycerin PatchNitroglycerin130$4,184
Cilostazol293$3,196
ClopidogrelClopidogrel Bisulfate369$2,210
Methylprednisolone18$128
Diltiazem 24hr ErDiltiazem Hcl11$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$915$147,525207 claims
PfizerEliquis$119$102,950119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Lenoir

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →